This trial is evaluating whether B/F/TAF (Adult Strength) will improve 6 primary outcomes and 36 secondary outcomes in patients with Human Immunodeficiency Virus Type 1 (HIV-1) Infection. Measurement will happen over the course of Week 1.
This trial requires 122 total participants across 8 different treatment groups
This trial involves 8 different treatments. B/F/TAF (Adult Strength) is the primary treatment being studied. Participants will be divided into 8 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 & 3 and have had some early promising results.
A person experiencing symptoms of AIDS has the following disease stages: (1) stage of infection with HIV; (2) AIDS symptoms; (3) immune system dysfunction; and (4) severe immune system dysfunction.
HIV-1 infection is acquired at different ages by different routes. The age at sexual debut has an effect on the risk of acquiring the virus. The age of acquiring HIV-1 infection influences the risk of presenting with AIDS.
HIV-1 seroprevalence is increasing in the US. In 2010, the virus was detectable in 2.4 million US citizens and 2.5 million resident non-citizens. More than 1 million US citizens were infected with HIV. These trends do not seem to be related to incidence.
The available data suggest that an effective vaccine cannot be developed as yet. However, recent developments suggest that it will be possible in the near future. HIV-1 virus and its components (nucleic acid) play a critical role throughout the entire life cycle for its transmission. Understanding the structure and dynamics of the virus and its components (nucleic acids) has been fundamental to this development of vaccine and its practical applications to control the virus in the body and to eradicate HIV-1 from humans and other primates in animal experiments. Currently, the goal of developing a curative vaccine in humans is not achievable.
Treatment regimes for HIV-1 infection vary and can be complex depending on the nature of the infection, the number, or severity of previous infections, and the patient's tolerance to therapies. Clinicians have used a range of antiretroviral drugs to treat HIV-1-associated diseases. Current therapies may provide effective long-term management although most have significant toxicities, such as the development of osteoporosis, a risk factor for fracture when HIV-1-associated osteopenia is present.
HIV-1 infection is a pandemic infectious disease that is one of the main causes of pediatric mortality within the world. HIV-1 infection is primarily transmitted through sexual and vertical transmission. Transmission of HIV-1 occurs through contact with blood and body fluids and through the transmission via breast feeding. Human infections are typically characterized by the acquisition of HIV-1 by contact with an HIV-1-infected person. HIV-1 infection can be confirmed biochemically and serologically with the aid of HIV-1 ELISA assay methodologies and Western blotting methodologies and by polymerase chain reaction (PCR) assays for viral genomic material.
It is important for physicians and patients to keep up to date with current research as information is constantly evolving. The studies cited in the following sections offer insights into new insights into HIV.\n- Researchers have conducted an open-label study that has been ongoing since November 2008 to determine whether the drug efalizumab, when administered with a protease inhibitor drug, decreases the risk of developing an infection in patients with HIV-1 who have not been treated with antiretroviral therapy. The study began in late 2008 and concluded in late 2010.
There are no newly discovered treatments for HIV-1 infection, but therapies continue to improve dramatically due to advances in AIDS research and treatment. There are still many unanswered questions left in HIV-1 biology and treatment response that need to be investigated. Although there are more discoveries annually than ever before, there will still be many unanswered questions the future and progress in AIDS research will offer.
Clinical trials for hiv-1 infection are underrepresented among African-American/African-American females with a lifetime risk of HIV infection ≥20% (defined as >80% if tested) who may be eligible to participate. [Age, HIV testing] have a marked inverse relationship to enrollment in clinical trials. Therefore, targeted outreach campaigns (through health personnel and other members of the LGBT community) in high incidence areas may be essential to increase enrollment in clinical trials for hiv-1 infection.
There is still work to be done prior to BFTAS gaining full governmental support, but the research is currently leading the way. While the progress is evident on the development of BFTAS, the major challenge is to create an effective and safer sublingual formulation of BFTAS.
Exposure of healthy blood donors to HIV/AIDS-associated viruses or to B,F, and T is safe. No significant risk of exposure was observed in donation profiles associated with increased HIV exposure. Results from a recent paper challenge the consensus that B-linked traits are inherently higher risk.
b/f/taf is a versatile tool for the study of RNA polymerase regulation by small RNAs in plant leaves. It enables the identification of tmts with differing roles in b/f-directed RNA polymerase maturation, which opens the way to dissect their function. Overall, this study suggests that a novel mode of action by plant tmts, i.e., alteration of RNA polymerase activity, may provide benefits in terms of plant fitness.